KR20250004953A - 순환하는 단백질을 분해하기 위한 이-작용성 분자 - Google Patents
순환하는 단백질을 분해하기 위한 이-작용성 분자 Download PDFInfo
- Publication number
- KR20250004953A KR20250004953A KR1020247033971A KR20247033971A KR20250004953A KR 20250004953 A KR20250004953 A KR 20250004953A KR 1020247033971 A KR1020247033971 A KR 1020247033971A KR 20247033971 A KR20247033971 A KR 20247033971A KR 20250004953 A KR20250004953 A KR 20250004953A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- alkyl
- linker
- group
- mif
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/08—Polyoxyalkylene derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/695,259 US20230097887A1 (en) | 2018-04-09 | 2022-03-15 | Bi-functional Molecules to Degrade Circulating Proteins |
| US17/695,259 | 2022-03-15 | ||
| PCT/US2023/064436 WO2023178179A2 (en) | 2022-03-15 | 2023-03-15 | Bi-functional molecules to degrade circulating proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250004953A true KR20250004953A (ko) | 2025-01-08 |
Family
ID=88024435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247033971A Pending KR20250004953A (ko) | 2022-03-15 | 2023-03-15 | 순환하는 단백질을 분해하기 위한 이-작용성 분자 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4493220A2 (https=) |
| JP (1) | JP2025509736A (https=) |
| KR (1) | KR20250004953A (https=) |
| CN (1) | CN119212726A (https=) |
| AU (1) | AU2023234543A1 (https=) |
| IL (1) | IL315581A (https=) |
| MX (1) | MX2024011358A (https=) |
| WO (1) | WO2023178179A2 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2997444A1 (en) * | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors for reducing cholesterol levels |
| US12364766B2 (en) * | 2018-04-09 | 2025-07-22 | Yale University | Bifunctional small molecules to target the selective degradation of circulating proteins |
| WO2019199621A1 (en) * | 2018-04-09 | 2019-10-17 | Yale University | Bi-functional molecules to degrade circulating proteins |
| CN113301925A (zh) * | 2018-12-19 | 2021-08-24 | 小利兰·斯坦福大学理事会 | 用于溶酶体靶向的双官能分子以及相关的组合物和方法 |
| IL294515A (en) * | 2020-01-31 | 2022-09-01 | Avilar Therapeutics Inc | Compounds bind asgpr to degrade extracellular proteins |
-
2023
- 2023-03-15 EP EP23771634.5A patent/EP4493220A2/en active Pending
- 2023-03-15 WO PCT/US2023/064436 patent/WO2023178179A2/en not_active Ceased
- 2023-03-15 AU AU2023234543A patent/AU2023234543A1/en active Pending
- 2023-03-15 CN CN202380040375.8A patent/CN119212726A/zh active Pending
- 2023-03-15 JP JP2024555118A patent/JP2025509736A/ja active Pending
- 2023-03-15 KR KR1020247033971A patent/KR20250004953A/ko active Pending
- 2023-03-15 IL IL315581A patent/IL315581A/en unknown
-
2024
- 2024-09-13 MX MX2024011358A patent/MX2024011358A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023178179A3 (en) | 2023-10-26 |
| AU2023234543A1 (en) | 2024-10-03 |
| CN119212726A (zh) | 2024-12-27 |
| EP4493220A2 (en) | 2025-01-22 |
| WO2023178179A2 (en) | 2023-09-21 |
| MX2024011358A (es) | 2025-01-09 |
| JP2025509736A (ja) | 2025-04-11 |
| IL315581A (en) | 2024-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240083859A1 (en) | Bi-functional Molecules To Degrade Circulating Proteins | |
| US20250332274A1 (en) | Bifunctional small molecules to target the selective degradation of circulating proteins | |
| AU2022205269B2 (en) | A conjugate of a tubulysin analog with branched linkers | |
| AU2022215217B2 (en) | Conjugation linkers containing 2,3-diaminosuccinyl group | |
| US12083181B2 (en) | Bi-functional molecules to degrade circulating proteins | |
| ES2892550T3 (es) | Compuestos útiles como inmunomoduladores | |
| AU2019384136B2 (en) | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists | |
| US12485178B2 (en) | Bifunctional small molecules to target the selective degradation of circulating proteins | |
| KR20240166514A (ko) | 순환하는 단백질의 선택적인 분해를 표적화하는 이작용성 소 분자 | |
| UA127808C2 (uk) | Похідна пладієноліду (варіанти) як засіб, що здійснює цілеспрямований вплив на сплайсосому, для лікування раку | |
| KR20250172727A (ko) | 순환성 단백질의 선택적 분해를 표적화하는 이중기능성 소분자 | |
| IL322897A (en) | Camptothecin derivatives and conjugates, methods for their preparation and medical uses | |
| JP2025538619A (ja) | 抗腫瘍化合物及びその応用 | |
| WO2025149012A1 (zh) | Dolastatin衍生物及其制备方法和应用 | |
| KR20250004953A (ko) | 순환하는 단백질을 분해하기 위한 이-작용성 분자 | |
| CN120569222A (zh) | 包含bcl-2家族蛋白降解剂的抗体药物偶联物及其制备方法和用途 | |
| HK40042237A (en) | Bifunctional small molecules to target the selective degradation of circulating proteins | |
| WO2024131843A1 (zh) | 一种抗体药物偶联物及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |